Skip to content
glp1.howSign in

Supportive Health

How GLP-1 medications affect men vs. women: what the sex differences actually are

The same GLP-1 medication doesn't act quite the same in men and women. On average women lose more weight, report more side effects, and absorb more of the drug at the same body weight, differences driven partly by estrogen and testosterone. This guide covers what the research shows about sex differences in weight loss, tolerability, blood sugar and biology, and what it means for what you should expect.

By the glp1.how editorial teamReviewed 4 min read

Evidence-backed

In the STEP trials of semaglutide, women lost markedly more weight than men on the same drug: 14.0% versus 8.0% of body weight in one trial, 16.2% versus 9.3% in another (Börchers & Skibicka, Endocrinology, 2025, DOI (external link)). GLP-1 medications aren't sex-neutral. On average they work harder in women, women report more side effects, and the sexes even absorb the drug differently. Some of that traces to estrogen and testosterone.

Women tend to lose more weight

Across GLP-1 analogs, women lose more weight than men on average. In the semaglutide STEP program the gap was consistent: 14.0% vs 8.0% (STEP 1), 7.5% vs 4.6% (STEP 2), and 16.2% vs 9.3% (STEP 4), women versus men (Börchers & Skibicka, Endocrinology, 2025, DOI (external link)).

The obvious explanation is that women are smaller, so a standard dose goes further. That's part of it, but at the same body weight women had about 32% higher drug exposure than men on liraglutide, and the review notes that even women who weighed more than the men still lost more. The drug appears to do more per milligram in women.

Side effects: more reports from women, but a mixed picture on stopping

Adverse-effect reports ran 28% higher in women for liraglutide and 41% higher for dulaglutide (Börchers & Skibicka, Endocrinology, 2025, DOI (external link)).

The evidence on stopping treatment is weaker. In one study that wasn't designed to detect sex differences, nearly 50% more women than men discontinued (a difference that wasn't statistically significant), and about twice as many women stopped because of gastrointestinal side effects (a trend, not a firm result). Other trials, including SUSTAIN 6, found no sex difference in discontinuation.

In practice, the same titration schedule may feel harder for some women, and slowing the dose climb or leaning on nausea strategies can make the difference between staying on the medication and quitting. Our guides on managing nausea and when a prescriber might slow your titration are especially relevant here.

Blood sugar: a smaller, less consistent gap

For blood-sugar control (HbA1c), the sex difference is less consistent than it is for weight, though where a difference shows up it again tends to favor women. Older postmenopausal women don't show the pronounced response younger women do, one of several clues that estrogen is part of the mechanism (Börchers & Skibicka, Endocrinology, 2025, DOI (external link)).

Why sex matters here: estrogen and testosterone

Sex hormones interact directly with the GLP-1 system.

  • Estrogen amplifies GLP-1's effect on appetite. In lab studies, estrogen enhances GLP-1's action on food-motivated behavior, removing estrogen (ovariectomy in animals) blunts the response, and a designed GLP-1–estrogen combination produced synergistic weight loss. Women also secrete more of their own GLP-1 in the luteal phase of the menstrual cycle than in the follicular phase. Together these help explain both the bigger effect in women and why it fades after menopause.
  • Testosterone works on the same pathway in men. Androgens like dihydrotestosterone amplify the incretin effect of GLP-1 and increase GLP-1 receptor expression, a male counterpart to the estrogen findings (Börchers & Skibicka, Endocrinology, 2025, DOI (external link)).

There's a social difference too: in US prescription data cited in the same 2025 review, women made up over 75% of the youngest (18–25) patients taking these medications.

The questions each sex should be asking are different, too

Beyond how the drug behaves, men and women face different considerations on a GLP-1:

  • For men, the main ones are testosterone (weight loss often raises it) and fertility (GLP-1s tend to preserve it, unlike testosterone therapy), covered in men's health on a GLP-1.
  • For women, the main ones are contraception and pregnancy (tirzepatide can make birth-control pills less reliable, weight loss can restore fertility, and these drugs aren't used in pregnancy) and PCOS, covered in women's health on a GLP-1.

What this means for you

These are group averages, not predictions about any one person. Plenty of men are strong responders and plenty of women tolerate the medication easily. Standard doses are not sex-adjusted on the label, so this isn't a reason to change your dose on your own. It's context for setting expectations and for speaking up about side effects. The core advice is the same for both sexes: protect muscle with resistance training and enough protein while you lose weight. Where sex does help is in knowing what to expect. Women may want to plan for a stronger weight response and possibly a rockier start, and both men and women benefit from knowing which hormone questions apply to them. It's worth bringing up with your prescriber.

This article is general education, not medical advice. Sex differences here are group averages and don't dictate any individual's dose or response. Decisions about dosing and side effects belong with your prescriber. Research findings above are attributed to PubMed-indexed articles with DOI links.

sex-differencesmenwomenweight-lossside-effectsestrogentestosteronesupportive-health

Common questions

Questions people often ask about this topic.

  • Do women lose more weight than men on a GLP-1?

    On average, yes. In the semaglutide STEP trials women lost markedly more, for example 14.0% vs 8.0% of body weight in one trial and 16.2% vs 9.3% in another, women versus men. It isn't only because women are smaller: at the same body weight, women had about 32% higher drug exposure. These are group averages, though, and plenty of individual men are strong responders.

  • Why do women get more side effects on a GLP-1?

    Women report adverse effects more often: reports ran 28% higher in women for liraglutide and 41% higher for dulaglutide. The evidence on stopping treatment is weaker. One study found nearly 50% more women than men stopped (not statistically significant) and about twice as many stopped for GI side effects (a trend), while other trials found no difference. Higher drug exposure in women likely plays a part. In practice, some women benefit from a slower dose climb and active nausea management.

  • Why does sex change how a GLP-1 works?

    Sex hormones interact directly with the GLP-1 system. Estrogen amplifies GLP-1's effect on appetite, which helps explain both the larger response in women and why it's less pronounced after menopause. Testosterone works on the same pathway in men, amplifying the incretin effect. The differences track real biology.

  • Should men and women take different GLP-1 doses?

    Not on your own. Standard doses are not sex-adjusted on the label, and this research is context for setting expectations, not a reason to change your dose. It does suggest women may want to expect a stronger weight response and possibly a rockier start, and to ask for slower titration or side-effect support if needed. Any dosing change is a conversation with your prescriber.

  • Are the health questions different for men and women on a GLP-1?

    Yes. For men, the main issues are testosterone (weight loss often raises it) and fertility (GLP-1s tend to preserve it, unlike testosterone therapy). For women, the main issues are contraception and pregnancy (tirzepatide can make birth-control pills less reliable, weight loss can restore fertility, and these drugs aren't used in pregnancy) plus PCOS; our women's health guide covers these. Both sexes should protect muscle with strength training and protein.

Evidence

The sources behind this article, labeled by type and strength.

Supporting4

Revision history

Updated 3 times since Sep 2, 2026 · show changes
  1. v4

    Evidence sources revised

  2. v3

    Common questions revised

  3. v2

    Summary rewritten; Body revised

  4. v1

    Change tracking began

Related guides

  • Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching · For men, losing weight on a GLP-1 can raise testosterone that obesity was holding down, and unlike testosterone therapy it seems to leave fertility intact. This guide covers what the research shows so far on testosterone, sexual function and sperm, muscle and bone, heart health and sleep apnea, and why the routine checkup matters more on these medications.
  • HRT for men (testosterone) and GLP-1 medications: what the connection really is · Low testosterone and excess weight are linked, but the cause often runs from the weight to the testosterone, and that changes when testosterone therapy actually helps. This guide covers who benefits from TRT and why losing weight on a GLP-1 can raise testosterone on its own.
  • CPAP as the weight comes off: managing sleep apnea on a GLP-1 · Tirzepatide (Zepbound) roughly halved sleep apnea severity in the SURMOUNT-OSA trials, and 42 to 50% of participants reached the trial's definition of resolution. That still left many with apnea, and the trials never tested stopping CPAP for good. This guide covers why you shouldn't retire your machine on your own, how pressure and mask fit change as weight comes off, when and how a repeat sleep test happens, and how an OSA diagnosis affects Zepbound coverage (as of September 2026).
  • Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps · Losing a lot of weight usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. So far the fracture data are reassuring and the drug itself does not look like the main cause, but the long-term evidence is thin. Here's what the bone-density and fracture studies show, who should pay the most attention, and the levers that kept bone steady in trials: resistance and impact training, protein, calcium and vitamin D, and a well-timed bone scan.
  • Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching · For women, the biggest GLP-1 question is fertility. Tirzepatide can make the pill less reliable, weight loss can bring back ovulation you weren't expecting, and none of these drugs is safe in pregnancy, which is why "Ozempic babies" happen. This guide covers contraception and pregnancy planning, the PCOS trial evidence, protecting bone and muscle, the heart, and the menopause overlap.
  • Cortisol, stress, and weight on a GLP-1: what the connection really is · The "cortisol makes you fat" story is mostly overstated. Real cortisol excess, as in Cushing's syndrome, clearly drives central fat, but everyday stress does far less. On a GLP-1, cortisol matters more for muscle than for belly fat. This guide covers the evidence, how sleep affects cortisol, and why "cortisol-blocker" supplements don't hold up.

Related terms

  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Liraglutide · A first-generation GLP-1 receptor agonist taken as a daily injection, sold as Victoza for type 2 diabetes and Saxenda for weight management, and now also as a US generic.
  • Titration · The gradual, step-by-step increase of a medication dose over time, used to reduce side effects.
  • Incretin · A class of gut hormones, including GLP-1 and GIP, that trigger insulin release in response to food.
  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • Polycystic ovary syndrome (PCOS) · A common hormonal condition in women involving irregular or absent periods, higher androgen levels, and frequently insulin resistance and weight gain; GLP-1 medications are increasingly used for weight management in PCOS.
  • Resistance training (progressive overload) · Exercise that loads your muscles against resistance and is made gradually harder over time (progressive overload) to keep or build muscle and strength.

Was this helpful?

Improve this page